LENSAR (LNSR) Proxy Filing summary

Executive summary

• A definitive merger agreement was signed for the acquisition of all outstanding shares at $14.00 per share in cash, plus a contingent value right (CVR) of up to $2.75 per share if a milestone is met, for a total potential consideration of $16.75 per share.

• The CVR milestone is the achievement of 614,000 cumulative procedures with the company's products between January 1, 2026, and December 31, 2027.

• The transaction is valued at up to approximately $430 million and is expected to close in mid-to-late 2025, subject to regulatory and shareholder approval.

• A $10 million deposit will be made by the acquirer, with specific provisions for its return or retention depending on deal completion or termination circumstances.

• The board unanimously approved the merger and recommends shareholder approval.

Voting matters and shareholder proposals

• A special shareholder meeting will be called to vote on the merger agreement and related transactions.

• A voting agreement was executed with affiliates holding approximately 45.8% of voting power, committing them to support the merger.

• Shareholders will receive a proxy statement with detailed information about the merger and their rights.

Board of directors and corporate governance

• The board of directors and officers of the surviving corporation will be those of the merger subsidiary immediately prior to the effective time.

• The board received a fairness opinion from its financial advisor regarding the merger consideration.

• The board retains the right to change its recommendation in response to a superior proposal, subject to certain procedures.